TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Updates from the KarMMa trial

Featured:

Nikhil MunshiNikhil Munshi

Jul 2, 2020


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. In this podcast, he discusses the recent updates from the KarMMa phase II trial (NCT03361748), in patients with relapsed/refractory multiple myeloma.

Updates from the KarMMa trial

Nikhil Munshi describes the mechanism of action of the idecabtagene vicleucel (ide-cel) BCMA targeting CAR T-cell therapy before detailing the study design. He then provides results from the 128 patients enrolled in the study, including and dose-response rates, overall response rates, complete response rates, and MRD negativity rates. He also describes the safety profile including cytokine release syndrome, neurotoxicity and cytopenias. These results demonstrate deep and durable responses for a heavily pre-treated patient population with relapsed/refractory multiple myeloma.